{"id":"NCT00141271","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression","officialTitle":"A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients With Bipolar I Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2005-09-01","resultsPosted":"2009-03-24","lastUpdate":"2021-03-25"},"enrollment":536,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Geodon (Ziprasidone)","otherNames":[]},{"type":"DRUG","name":"Geodon (Ziprasidone)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"20-40mg BID arm","type":"ACTIVE_COMPARATOR"},{"label":"60-80mg bid arm","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.","primaryOutcome":{"measure":"Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score","timeFrame":"Baseline to 6 weeks","effectByArm":[{"arm":"120-160mg Ziprasidone","deltaMin":-6.07,"sd":0.62},{"arm":"40-80 mg Ziprasidone","deltaMin":-7.66,"sd":0.73},{"arm":"Placebo","deltaMin":-5.75,"sd":0.65}],"pValues":[{"comp":"OG000 vs OG002","p":"0.6409"},{"comp":"OG001 vs OG002","p":"0.0140"},{"comp":"OG000 vs OG002","p":"0.4840"},{"comp":"OG001 vs OG002","p":"0.4444"},{"comp":"OG000 vs OG002","p":"0.8129"},{"comp":"OG001 vs OG002","p":"0.1105"},{"comp":"OG000 vs OG002","p":"0.9582"},{"comp":"OG001 vs OG002","p":"0.1893"},{"comp":"OG000 vs OG002","p":"0.2924"},{"comp":"OG001 vs OG002","p":"0.1897"},{"comp":"OG000 vs OG002","p":"0.6608"},{"comp":"OG001 vs OG002","p":"0.2148"},{"comp":"OG000 vs OG002","p":"0.5290"},{"comp":"OG001 vs OG002","p":"0.0811"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":72,"countries":["United States"]},"refs":{"pmids":["25012414","23609405"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281136&StudyName=A%20Six-Week%20Study%20Evaluating%20The%20Efficacy%20And%20Safety%20Of%20Geodon%20In%20Patients%20With%20A%20Diagnosis%20Of%20Bipolar%20I%20Depression"]},"adverseEventsSummary":{"seriousAny":{"events":7},"commonTop":["Somnolence","Headache","Nausea","Insomnia","Sedation"]}}